Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is a globally recognized leader in serving science, playing a pivotal role in the biopreservation market with its extensive and diverse product portfolio. The company is a top provider of essential biopreservation equipment and consumables, including advanced freezers, refrigerators, centrifuges, and specialized cryopreservation media. These products are widely utilized by biobanks, gene banks, and hospitals worldwide for the long-term, stable storage of biological and genomic samples at cryogenic temperatures. Thermo Fisher’s strategy for market dominance involves continuous product innovation and launches, exemplified by its high-performance, ultra-low temperature (ULT) freezers that feature enhanced energy efficiency and temperature stability for optimal sample preservation. Furthermore, the company offers crucial infrastructure and services for the storage of sensitive biological materials, supporting national research programs and clinical trials globally. Thermo Fisher also strengthens its position through strategic business expansions and acquisitions, enhancing its specialty diagnostics and overall service offerings, thereby cementing its role as a key enabler of research and clinical practice in the biopreservation ecosystem.
Latest Market Research Report on Biopreservation Download PDF Brochure Now
Merck KGaA
Merck KGaA, a leading German science and technology company, is a dominant force in the biopreservation market, primarily operating through its subsidiary, Sigma-Aldrich Corporation. The company leverages its comprehensive life science and chemical portfolio to provide crucial materials for biological sample preservation, including high-quality cryopreservation media and reagents. Merck’s significant market share, which was second-largest in 2023, is driven by its strong revenue base, particularly from Europe, and its strategic focus on geographical expansion into high-growth regions like Asia Pacific and North America. Merck’s efforts to enhance its presence involve establishing new life science centers and engaging in expansion activities to increase its global customer base. The company’s commitment to advancing the entire life science value chain is evident in its cutting-edge offerings, such as providing the first fully integrated contract development and manufacturing organization (CTDMO) services for all stages of mRNA therapeutics, which are heavily dependent on reliable biopreservation and cold-chain management. Through innovation and global reach, Merck continues to provide the essential infrastructure and consumables required for robust biobanking and regenerative medicine applications.
Azenta, Inc.
Azenta, Inc. (formerly Azenta Life Sciences) is a key global player specializing in providing comprehensive, end-to-end solutions for the biopreservation and sample management lifecycle. The company offers a diverse range of products and services, including advanced, automated cryogenic storage systems such as the CryoArc Deca, which is designed for rapid box-level retrieval and enhanced operational efficiency in high-throughput biobanks. Azenta’s offerings extend beyond equipment to include cold-chain logistics and specialized sample management services, ensuring the integrity and security of biological materials throughout their entire preservation journey. A major strategic move to bolster its cold-chain capabilities was the acquisition of B Medical Systems, a leader in temperature-controlled storage and transportation solutions, significantly expanding Azenta’s global biopreservation logistics footprint. By combining sophisticated automation, temperature-controlled systems, and robust infrastructure like its new biorepository facilities, Azenta provides the necessary technological backbone for modern biological research, personalized medicine, and the demanding field of cell and gene therapy.
BioLife Solutions Inc.
BioLife Solutions Inc. is a globally recognized key player distinguished by its focus on proprietary biopreservation media and advanced cold chain management technologies, which are critical for the long-term stability and viability of sensitive biological specimens. The company’s innovative, pre-formulated preservation media are specifically designed to reduce delayed-onset cell damage (apoptosis) and maintain superior sample quality during the freezing, thawing, and storage processes, making them instrumental for the rapid growth of cell and gene therapy biobanks. A significant offering is the evo Cold Chain Management Platform, which supports numerous early-stage cell and gene therapy clinical trials by providing secure and monitored transport of highly valuable materials. Furthermore, BioLife Solutions has expanded its product line into high-capacity cryogenic equipment, exemplified by the launch of the IntelliRate i67C, a large-capacity controlled-rate freezer. By continuously innovating in both the consumable (media) and equipment segments, BioLife Solutions is a vital contributor to the regenerative medicine and biobanking sectors, enabling better therapeutic outcomes.
PHC Holdings Corporation
PHC Holdings Corporation, headquartered in Japan, is a significant contender in the biopreservation market, primarily recognized for its high-quality preservation equipment. The company held a leading share of the market in 2023 and is dedicated to manufacturing a specialized portfolio of laboratory and biomedical refrigeration products. Their offerings are essential for biobanks and research institutions, including various lab freezers, ultra-low-temperature freezers (ULT), pharmacy refrigerators, and biomedical freezers. PHC Holdings strategically focuses on organic growth through the continuous launch of improved and energy-efficient products, such as its ECO Vaccine Refrigerators and Laboratory Freezers, to maintain its strong presence in the market. The company’s commitment to providing reliable, temperature-controlled solutions ensures the optimal storage and long-term viability of biological samples, including vaccines and patient biospecimens. PHC Holdings’ equipment forms the critical infrastructure backbone for numerous academic and clinical organizations globally, supporting sensitive biological research and healthcare delivery.
Cryoport Inc.
Cryoport Inc. is a specialized global provider of sophisticated, temperature-controlled supply chain and logistics solutions, making it an essential service provider in the biopreservation ecosystem. The company is renowned for its advanced Cryoport Systems, which deliver secure, monitored, and compliant transport infrastructure for the highly sensitive materials used in the life sciences, particularly for cell and gene therapies and reproductive medicine. Cryoport’s expertise lies in managing the complex, regulatory-heavy cold chain demands of regenerative medicine and global biobank networks. Their proprietary Cryoport Express® shippers utilize state-of-the-art technology to maintain precise cryogenic temperatures (often down to -150°C or -190°C) and provide real-time location and condition monitoring throughout the entire transport process. By ensuring the integrity, security, and traceability of irreplaceable biological commodities like cells, tissues, and therapeutic products from the point of origin to the patient, Cryoport plays a critical, non-equipment role in enabling the clinical and commercial success of next-generation therapies.
Panasonic Corporation
Panasonic Corporation, a major technology company, is a key provider of specialized equipment within the biopreservation market, primarily focusing on advanced refrigeration and ultra-low temperature (ULT) storage systems. The company’s product line is vital for research laboratories and biobanks, offering reliable equipment such as ultra-low temperature freezers that can operate at temperatures as low as -150°C, and a variety of biomedical refrigerators and freezers. Panasonic’s systems are known for their high quality and temperature stability, which is essential for the long-term preservation of critical biological materials like engineered cell lines, DNA, RNA, and other biospecimens used in genomics and drug screening studies. The company’s commitment to high-performance, controlled-temperature storage solutions directly supports large-scale biobanking initiatives and sophisticated research programs globally. Through its robust equipment portfolio, Panasonic provides a foundational component of the cold chain infrastructure necessary for preserving the integrity and viability of biological samples for future use.
MVE Biological Solutions
MVE Biological Solutions, a brand within Chart Industries, is a leading specialist in providing cryogenic storage equipment to the biopreservation market. The company is primarily focused on manufacturing high-efficiency, static and mobile cryogenic freezers and liquid nitrogen storage systems designed for long-term biopreservation. MVE’s innovative product lineup, such as the MVE 1894R-190 model, is engineered to handle massive storage capacities, capable of securely holding tens of thousands of clinical cell therapy vials at extremely low temperatures, typically around -190°C. Their focus on bulk, reliable, and energy-efficient cryogenic storage makes them indispensable for large-scale biobanking and the rapidly expanding field of cell and gene therapy manufacturing. By delivering robust equipment that ensures prolonged sample viability and temperature consistency, MVE Biological Solutions addresses the critical need for secure and high-density cryostorage in the global biomedical and pharmaceutical industries.
Biomatrica, Inc.
Biomatrica, Inc. is a uniquely positioned company in the biopreservation market, specializing in advanced media solutions for room-temperature sample stabilization. Unlike companies focusing on cryogenic equipment, Biomatrica addresses the challenge of high-cost cryogenic storage and complex cold-chain logistics by developing proprietary stabilization media. Their innovative products, such as DNA stable and RNA stable, are designed to chemically protect and preserve biological samples, including nucleic acids, proteins, and cells, allowing for their long-term storage and shipment at ambient or room temperatures. This technology is crucial for applications in genomics, diagnostics, and biobanking, offering an energy-efficient, cost-effective, and logistically simpler alternative to traditional freezing methods. By focusing on media innovation, Biomatrica directly contributes to democratizing access to sample collection and storage, especially in decentralized settings and regions where cryogenic infrastructure is limited, making it a key enabler of distributed and field-based research.
LabVantage Solutions, Inc.
LabVantage Solutions, Inc. is a vital player in the biopreservation market, specializing not in equipment or media, but in the essential area of Laboratory Information Management Systems (LIMS). Their LIMS platforms are indispensable for the digital management, traceability, and operational compliance of large-scale biobanking and sample repositories. The LabVantage LIMS provides a sophisticated system for data management of preserved samples, enabling robust inventory control, tracking, and auditing of biological specimens—including cells, tissues, and genetic material—as they move through the biopreservation workflow. This technology is critical for maintaining regulatory compliance, ensuring data accuracy, and linking a sample’s physical location and condition data to its vast associated genomic and clinical metadata. Given the soaring number of storage facilities and the increasing complexity of data associated with personalized medicine and clinical trials, LabVantage’s focus on information management is central to supporting the quality, security, and long-term utility of bio-preserved samples globally.
Latest Market Research Report on Biopreservation Download PDF Brochure Now